RESULTS OF TRIALS Denovo ADVAGRAF with MMF or m TOR Conversion from - PowerPoint PPT Presentation

RESULTS OF TRIALS • Denovo ADVAGRAF with MMF or m TOR • Conversion from prograf or CsA • Association with m TORI

Summary • Advagraf is associated with lower trough level variability and better compliance • Compared to prograf in terms of graft survival, rejection and gfr is non-inferior • Compared to cyclosporine , in terms of graft survival, rejection , gfr is noninferior although in one study creatinine clearance in adva group was significantly better. • Compared to csa, is associated with better control of ht and better lipid profile. • CAN BE STARTED AS: - DE NOVO ( preferentially with induction ) - EARLY OR LATE CONVERSION FROM PROGRAF OR CsA - COMBINATION WITH m TOR • AUC MAY DECREASE IN FIRST DAYS BUT IN CLINICAL TRIALS IS WAS NOT ASSOCIATED WITH INCREASED RISK OF AR.

Thank you all for your attention